Drug Profile


Alternative Names: BI 10773/BI 1356; BI 10773/linagliptin; BI 1356/BI 10773; BI 1356/empagliflozin; Empa/Lina FDC; Empagliflozin/BI 1356; Glyxambi; Linagliptin/BI 10773; Linagliptin/empagliflozin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 16 Jun 2017 Boehringer Ingelheim and Eli Lilly completes a phase III trial in Type-2 diabetes mellitus in Japan (NCT02489968)
  • 27 Mar 2017 Boehringer Ingelheim and Eli Lilly complete a phase III trial for Type-2 diabetes mellitus in Japan (NCT02453555)
  • 04 Jan 2017 US FDA approves sNDA to include data, demonstrating empagliflozin reduces the risk for cardiovascular death, in product labels for empagliflozin/linagliptin in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top